The 2019 BIO International Convention formally opened today, on June 4. The Vice Minister Dr. Dar-Bin Shieh, Ministry of Science and Technology (MOST), lead a delegation of start-up teams under the MOST's GLORIA program attending this event. And each one of the teams engage in a "one by one pitch" with SmartLabs, which was founded in 2015. Within three years, the coaching team has created 7 IPO, which raised a total of 7 billion US dollars with a 28% successful rate. Today these start-up teams will have chance in accelerating incubation and entering international markets through the contact with SmartLabs.
The seven teams of GLORIA delegation are carefully selected by The Department of Academia-Industry Collaboration and Science Park Affairs from National Taiwan University、National Yang-Ming University、National Taiwan Ocean University and National Central University GLORIA, focusing in precision treatment, prospective drugs, and AI-based medical treatments.
The Vice Minister Dr. Dar-Bin Shieh mentioned that Taiwan has outstanding capabilities in information and communications industries, along with a well-known and solid medical system. Through this interaction, many accelerators and incubation centers in the Boston area are very optimistically looking for future cooperation with Taiwan. Especially with SmartLabs stating it will create win-win cooperation in the future.
Dr. Amrit Chaudhuri mentions that he is interested in several GLORIA teams and is positive about Taiwan's original creative energy, and provided some business model suggestions for Goldsitron precision therapy targeted sensitization enhanced radiotherapy from Yangming University. He also points that temperature-sensitive cell capture coating from National Central University will provide key continuous cell manufacturing advantages in the value chain in emerging cell therapy and regenerative medicine industry. For the AHEAD team from NTU, not only there are clinical physicians and information scientists, but also real application by combining AI algorithm and machine learning that provides pioneering assistant tool in the clinical diagnosis and decision making for clinical physicians in leukemia and lymphoid cancer.
Dr. Dar-Bin Shieh, the Vice Minister of MOST, also mentions that biomedical industry is the core of growth impulse in next generation industry of Taiwan. Under the full support of Taiwan Biomedical Industry Innovation Program, Taiwan will construct biomedical ecosystem for sustaining the growth of this focusing area.
SmartLabs is collaborating with MOST and plans to establish new site in Hsinchu Biomedical Science Park, assisting Taiwan’s biomedical industry to enter the global value chain/supply chain, and expand overseas market.
Mr. Ming Che Lin
Department of Academia-Industrial Collaboration and Science Park Affairs, Ministry of Science and Technology (MOST)
Tel : +886-2737-7212
From left to right：台灣大學莊曜宇博士、科技部產學司科長林明徹、中央產學聯盟主任曹嘉文、科技部產學司副司長涂君怡、科技部生科司司長莊偉哲、科技部次長謝達斌、
SmartLabs CEO Seth Taylor、SmartLabs CBO/CFO Amrit Chaudhuri、SmartLabs Hans Ludi、科技部駐波士頓辦事處科技組組長謝水龍、SmartLabs Daisy Riquelme